Compare Baxter International Inc (BAX) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Atlassian Corporation PLC — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Atlassian Corporation PLC trades at $153.56 (market cap $38.54B). The key difference: Atlassian Corporation PLC is far larger — about 2.7× Baxter International Inc's market cap, and Baxter International Inc pays a 0.14% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| BAX | TEAM | |
|---|---|---|
Market Cap | $14.36B | $38.54B |
Sector | Health | Technology |
52-Week High | $28.35 | $182.36 |
52-Week Low | $15.80 | $57.15 |
Enterprise Value | $21.88B | $38.53B |
Dividend Yield | 0.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Atlassian Corporation (TEAM) surged 35.31% to $149.07 following a strong Q4 2026 earnings beat, with revenue up 28% year-over-year to $1.77 billion and cloud revenue accelerating to 31%. The stock is trading near its pivot point of $148, with bullish technical signals from moving averages but overbought RSI readings. Analysts maintain a strong buy consensus with a $161.93 price target, citing enterprise deal expansion and AI platform adoption as key growth drivers.
Outlook remains positive due to robust revenue growth and margin improvement, but risks include high valuation multiples (P/S 5.9, EV/EBITDA 178.27) and persistent net losses. Investors should weigh the company's cloud momentum against profitability challenges and macroeconomic uncertainty impacting software demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
